HC Wainwright & Co. Maintains Buy on Evommune, Lowers Price Target to $50

Benzinga Newsdesk www.benzinga.com Neutral 76.7%

Neg 0% Neu 76.7% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Evommune (NYSE:EVMN) with a Buy and lowers the price target from $65 to $50.